| Identification | Back Directory | [Name]
5-Methyl-2-[(3R)-3-methyl-4-morpholinyl]-4-(1-methyl-1H-pyrazol-5-yl)-7-(1H-pyrazol-3-yl)imidazo[1,5-b]pyridazine | [CAS]
2761193-67-1 | [Synonyms]
ATR-IN-29
5-Methyl-2-[(3R)-3-methyl-4-morpholinyl]-4-(1-methyl-1H-pyrazol-5-yl)-7-(1H-pyrazol-3-yl)imidazo[1,5-b]pyridazine | [Molecular Formula]
C19H22N8O | [MOL File]
2761193-67-1.mol | [Molecular Weight]
378.43 |
| Hazard Information | Back Directory | [Uses]
ATR-IN-29 is a potent and orally active ATR kinase inhibitor with an IC50 value of 1 nM. ATR-IN-29 shows antiproliferative activity[1]. | [in vivo]
ATR-IN-29 (10 mg/kg; p.o.; once) shows good pharmacokinetic parameters with t1/2 of 1.64 h, Cmax of 9343 ng/mL, AUC0-t of 98507 ng·h/mL, AUC0-inf of 98517 ng·h/mL in CD-1 (ICR) mice[1]. | [IC 50]
ATR: 1 nM (IC50) | [References]
[1] Sui Xiong Cai, et al. Substituted imidazo[1,5-b]pyridazine compounds as kinase inhibitors and use thereof. WO2022135560A1. |
|
|